The STAY study is the clinical trial for LOY-002, a senior dog program that recently earned its preliminary efficacy acknowledgment from the FDA. It’s the first FDA-concurred trial for a longevity drug, and at 1,000 dogs, is the largest clinical trial in the history of veterinary medicine. With solid interest from DVMs and dog owners, Loyal is enrolling an additional 300 dogs in the study.
Source: Loyal, April 14, 2025. Link. LOY-002 is a daily flavored tablet developed for dogs aged 10 and older weighing at least 14 pounds <Link>.
Leave a Reply